论文部分内容阅读
近年来,FDA指南建议以患者自报结果作为临床试验的终点。根据该指南提供的方法,Cella D等筛选了晚期癌症患者的症状指标。他们纳入了NCCN成员机构和4个非营利性社会公益组织的533例癌症患者,其诊断包括膀胱癌、脑癌、乳腺
In recent years, the FDA guidelines recommend using patient self-reported outcomes as the endpoint of a clinical trial. According to the guidelines provided by the method, Cella D and other screening for the symptoms of advanced cancer patients. They included 533 cancer patients from NCCN member institutions and four non-profit social welfare organizations whose diagnosis included bladder cancer, brain cancer, breast